Refractory Leukemia: Clinical Trials

3 trials for Refractory Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown. 3 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 3
Phase 11Unknown 1
Phase 31Unknown 1

Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease
Phase 2UnknownShanghai General Hospital, Shanghai Jiao Tong University School of Medicine302023-01-102023-06-28
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia
Phase 1 / Phase 2UnknownShenzhen University General Hospital202021-02-052021-12-20
Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
Decitabine, mBU/CY and ATG, mBU/CY - Stem Cell Transplant Complications, Relapse Leukemia
Phase 2 / Phase 3UnknownPeking University People's Hospital552018-12-012019-05-29

Narrower conditions

Leukemia (3)  ·  Lymphoma (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Broader conditions

Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Disease Attributes (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia, Lymphoid (1)  ·  Lymphatic Diseases (1)  ·  Lymphoproliferative Disorders (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Interventions

Decitabine (1)

Sponsors

Peking University People's Hospital (1)  ·  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)  ·  Shenzhen University General Hospital (1)

Countries

China (3)

Top investigators

Li Yu, Dr (1)  ·  Xianmin G Song (1)  ·  Xiao-Jun Huang (1)